

Frequency of helicobacter pylori infection in patients presenting with symptomatic cholelithiasis at tertiary care hospital, Karachi

Nimra Ali, Azfaruddin Qureshi, Sayed Ashraf Hassan, Ramsha Fareed, Farhina Salahuddin, Narmeen Farooq Panjwani

Abstract:

Background: Gallstones represent a significant burden for health care systems worldwide and are one of the most common disorders presenting to emergency room. It is becoming an increasingly common cause of morbidity, leading to hospital admission in the developing world. The bacterium *Helicobacter pylori* (*H. pylori*) has been implicated as a risk factor for various diseases including chronic gastritis, gastric ulcer, duodenal ulcer, and gastric cancer. *Helicobacter pylori* are believed to be a mediating factor for gastric and extragastric diseases. The gallbladder and bile duct may be two of the targets of chronic *H. pylori* infection.

Aim: To study the frequency of helicobacter pylori infection in patients presenting with symptomatic cholelithiasis at tertiary care hospital, Karachi.

Material and Methods: The study is conducted in Surgical Unit III, Abbasi Shaheed Hospital, Karachi to clarify the prevalence and investigate the correlation between *H. pylori* infection and gallstones. All patients with symptomatic gall stones admitted for laparoscopic or open cholecystectomy were included in the study. The method for *H. pylori* infection detection is stool antigen test.

Results: 165 patients were admitted in Surgical Unit III, Abbasi Shaheed Hospital, Karachi from January 2018 to July 2021 with symptomatic gallstones for Laparoscopic / Open cholecystectomy. 29 (17.57%) are males and 136 (82.41%) are females. 149 (90.30%) patients had laparoscopic cholecystectomy and 16 (9.69%) patients had open cholecystectomy. 11 (6.66%) patients had conversion of difficult laparoscopic to open cholecystectomy. *H. pylori* stool antigen was positive in 47 (28.48%) and had medical therapy for *H. pylori* before surgery.

Conclusion: Our result showed a significant positive correlation between *H. pylori* infection and symptomatic gall stones. *H. pylori* infection is closely related to an increased risk of cholelithiasis and chronic cholecystitis.

Keywords: *Helicobacter pylori* infection, gallstones, cholecystitis.

Introduction:

Gallstones represent a significant burden for health care systems worldwide. It was once considered a disease of western world but due to changes in food pattern and lifestyle, it is becoming an increasingly common cause of morbidity and the leading cause of hospital admission in the developing world. Its occurrence in West is 10% and in Asian population ranges from approximately 3%-15% and in Pakistan and the incidence of gall stones is about 4% and 14.2%

in males and females respectively.¹ Gallstone formation may be associated with a complex interaction of genetic and environmental factors such as female sex, family history, and ethnicity.² Lifestyle and some other metabolic disorders, high alcohol consumption, hyperlipidemia, fatty liver, and obesity also affect gallstone formation.³

Helicobacter pylori, is a gram negative bacillus, it has been recognized as a public hazard and approximately half of the world population has

Received

Date: 13th September, 2021

Accepted

Date: 21st February, 2022

Abbasi Shaheed Hospital, Karachi

N Ali

A Qureshi

SA Hassan

R Fareed

F Salahuddin

NF Panjwani

Correspondence:

Dr. Nimra Ali,
Resident General Surgery,
Surgical Unit-III, Abbasi
Shaheed Hospital, Karachi.
Cell No: +92 331-2435451
email: namraali_hps@
hotmail.com

Table 1: Age distribution

Age in years	No of patients	%ages
<20 years	4	2.42%
20-29 years	21	12.72%
30-39 years	38	23.03%
40-49 years	43	26.06%
50-59 years	34	20.60%
>60 years	25	15.15%

Table 2: Types of Cholecystectomy

Types of Cholecystectomy	No of patients
Laparoscopic Cholecystectomy	149 (90.30%)
Open Cholecystectomy	16 (9.69%)

Table 3: Frequency of H.Pylori infection

H.Pylori infection stool antigen test	Frequency	Percentages
Yes	47	28.48%
No	118	71.51%
Total	165	100.0%

H. pylori infection. The prevalence is thought to be 60%- 80% in developing countries and 30%–50% in developed countries and has been recognized as a public hazard worldwide.⁴ The reported prevalence of H. pylori in Pakistan was 49%.⁵ The other study showed the prevalence of H. pylori infection as 12.06%.⁶

Recently, the bacterium has been implicated as a risk factor for various extra-intestinal diseases including hepatobiliary diseases ranging from calcularcholecystitis and primary biliary sclerosing cholangitis to gallbladder cancer and primary hepatic carcinomas.⁷ Helicobacter pylori are believed to be a mediating factor for various gastric and extragastric disease. The gallbladder and bile duct may be two of the targets of chronic H. pylori infection and gallstones formation.

The study is designed to determine the frequency of H. pylori in patients presenting with symptomatic cholelithiasis in order to establish the local perspective as there is paucity of local

data. Early detection would help in establishing the magnitude of problem and on the basis of which effective and timely management can be done which would impact upon the progression of disease and its complications. Moreover, data from this study would provide the much needed local perspective as there is wide variation in prevalence of H. pylori infection in different regions of the world. We are burdened with a large population of patients with symptomatic cholelithiasis.

Material and Methods:

The study was conducted after permission from the institutional ethical review committee. Consenting cases, meeting inclusion criteria were enrolled in the study from the Surgical Unit III, Abbasi Shaheed Hospital, Karachi. Informed consent was obtained from all the patients for assigning them to the study and using their data in research. Brief history about duration of illness and demographic information was taken at the time of admission.

All patients with symptomatic gallstones admitted for laparoscopic or open cholecystectomy were included in the study. Non-consenting patients, patients who have taken H-pylori eradication therapy within 4 weeks duration, patients with history of perforated peptic ulcer or patients unfit for general anesthesia and Surgery were excluded.

Stool sample was sent before surgery for H. pylori stool antigen test (SATs). The stool immunoassay test uses a polyclonal anti-H. pylori and is developed to identify current infection by detecting antigen(s) that are produced and shed into the stool by live H. pylori bacteria. All H pylori stool antigen positive patients were treated with triple therapy for 14 days before surgery.

Results:

165 patients were admitted in Surgical Unit III, Abbasi Shaheed Hospital, Karachi from January 2018 to July 2021 with symptomatic gallstones for Laparoscopic/Open cholecystectomy. 29(17.57%) were males and 136(82.41%) were females. Mean age of 43.87±11.21. Majority of

patients were between 30- 50 years 81(49.09%). [Table 1]

149(90.30%) patients had laparoscopic cholecystectomy and 16(9.69%) patients had open cholecystectomy. [Table 2] 11-patients had conversion of laparoscopic to open cholecystectomy due to difficult anatomy, 3-patients with Hepatitis C viral marker positive and deranged clotting profile, 2-patients had Mirizzi syndrome and impacted stone at the neck had open cholecystectomy. In cholecystectomy patients 41(24.84%) were diabetics and 54(32.72%) were hypertensive.

H. pylori stool antigen was positive in 47(28.48%) and treated by medical therapy before surgery. Data was analyzed on SPSS Version 20. Mean and standard deviation was calculated for continuous variables such as age and duration of symptoms.

Discussion:

Incidence of gallstones increases with age in all racial groups.⁸ In addition to ethnicity and genetics, advancing age, obesity and female gender are also risk factors for gallstones. Because of female sex hormones and increased cholesterol levels, females with obesity are more likely to get gallstones.⁹ However, the most significant risk factors for gallstone disease were patients with age >65 years and being overweight BMI>25.¹⁰ The incidence of H. pylori increases with age and the probability of detecting H. pylori in the bile increased steadily with increasing age.¹¹ In our study the gallstone disease is more common in females. 17.57% were male and 82.41% were female.

Helicobacter species have not been proved to induce histological injury to the biliary epithelium or liver parenchyma. The strongest association of the presence of these organisms in bile is with cholestatic conditions.¹² The presence of H. pylori in gallbladder wall mucosa might indicate a big risk for cholelithiasis. Several studies showed variable incidence of H.Pylori in symptomatic gallstones 10%-55%.¹³

In another study the presence of H. pylori in the gallbladders ranges from 33% to 37% of patients with symptomatic gallstones.¹⁴ In our study the infection rate of H.pylori in symptomatic gall stones is 47/165 (28.48 %). (Table 3) Helicobacter pylori infection of the gallbladder was significantly associated with cholelithiasis an increased risk of chronic cholecystitis and cholecystitis when compared with the control group. (24.98% vs. 8.28%, P<0.05).¹⁵

Several factors have been reported to play roles in the formation of gallstones, including bacterial infections in the gallbladder and bile ducts.¹⁶ It is known that increased incidence of hepatobiliary disease and risk of hepatobiliary cancer is associated with chronic carriage of Salmonella typhi in the gallbladder. Whether or not H. pylori has a similar relationship in patients with chronic cholecystitis can only be proved by a prospective study of hepatobiliary disease using appropriate tests for H. pylori diagnosis.

H. pylori was first described in the gallbladder mucosa in patients with gallstones in 1996, and a relationship between H. pylori and gallstone formation was reported. Bacteria closely similar to Helicobacter pylori detected immunohistologically and genetically in resected gallbladder mucosa.¹⁷ The survival of H. pylori is documented to be more favorable in low pH areas mostly in stomach.¹⁸ It remains unclear if H. pylori reaches the gallbladder and biliary tree via an ascending route from the duodenum, or via the portal venous system.¹⁹ Patients undergoing Endoscopic retrograde Cholangiopancreatography (ERCP) specially sphincterotomy reported that the procedure could result in contamination of the gallbladder with helicobacter strains via the ascending pathway from the duodenum. The stomach was colonized in nearly all patients with infected bile, and it is likely that the bacteria may have entered the bile ducts by reflux from the duodenum. Even the stones retrieved from common bile duct during ERCP may harbor H. pylori.²⁰

Hematogenous spread via the portal venous system to the liver and the excretion of the or-

ganisms into the bile is another pathway for the *H. pylori* spread. After translocation of *Helicobacter* species may colonize the biliary tract. Bile and gallbladder tissue samples were obtained from patients who underwent cholecystectomy for chronic cholecystitis with cholelithiasis. Patients with gallstones were 3.5 times as likely to have *H. pylori* in the bile compared with patients in a control group.²¹

Different mechanisms are responsible for the formation of pigmented gallstones and cholesterol gallstones. Recently, studies showed that *H. pylori* infection could have an important role in the formation of cholesterol gallbladder stones.²² Since *Helicobacter* species was detected from the gallbladder tissue, gallstone, and bile taken from the gallbladder specimen, and results have shown that *H. pylori*, may contribute to the formation of cholesterol gallstones.²³ Due to bile stasis *H. pylori* is relatively more colonized in bile in gallstone diseases and support the role of *H. pylori* in the development of cholecystitis in humans.²⁴ Dar et al,²⁵ also pointed an association between the presence of *H. pylori* and hepatobiliary stone diseases.

Diagnostic testing methods available for *H. pylori* include non-invasive and invasive techniques. Non-invasive techniques include serology, urea breath testing, and stool antigen detection of *H. pylori*. Serology testing is the least sensitive non-invasive technique. It has 75% to 85% sensitivity compared with 95% sensitivity for stool antigen and urea breath testing. Because of the high rate of false positives, serology test is no longer recommended in the United States. Stool antigen tests detect active infection, and excellent for pre-treatment or post-treatment testing, and are highly specific for *H. Pylori* infection.²⁶

Stool antigen test (SAT) detects the presence of *H. pylori* antigen in stool samples and has a good sensitivity and specificity, 94% and 97% respectively in global meta-analysis, in the diagnosis of *H. pylori* infection.²⁷ Stool antigen tests are easy to perform and do not require specialized equipment, which make it suitable for in-office test in developing countries. Moreover, SAT is a useful

tool for epidemiological study and screening programs.²⁸ There are two types of SATs used for *H. pylori* detection, enzyme immunoassay (EIA) an immunochromatography assay (ICA) based methods, using either polyclonal antibodies or monoclonal antibodies. EIA-based tests provide more reliable results than ICA-based tests.²⁹ With regard to cost and equipment, SAT is more suitable than urea breath test (UBT) for mass surveys. As compared with serological test, which are usually used for screening, SAT seems to provide more reliable results in diagnosis of *H. pylori* infection. The accuracy of SAT is influenced by several factors, like usage of antibiotic, Proton pump inhibitors, altered bowel movements and upper gastrointestinal bleeding. Preservation of the specimen, temperature, transport time before testing, and test cut-off value also have impact on the diagnostic accuracy of SAT.³⁰ *H. pylori* stool antigen testing are recommended as non-invasive tests for active *H. pylori* infection, as a basis for a "test-and-treat" strategy for *helicobacter pylori* in regions in which the prevalence of *helicobacter pylori* exceeds 20%.³¹

Serum anti-*H. Pylori* antibody test is an unreliable test for evaluating and eradication therapy because antibodies can be present in the blood for a long time even after successful eradication. Thus Serology is suboptimal for the diagnosis of active *H. pylori* infection.³²

Helicobacter pylori infection may be involved in the formation of brown pigmented gallstones. *Helicobacter pylori* can produce oxidative stress and free radical re-actions through the reactive oxygen species (ROS) and re-active nitrogen species (RNS) system 33 and release large amounts of pro inflammatory and vasoactive substances, such as interleukins (IL)-1, IL-6, and tumor necrosis factor (TNF)- α 34, which are involved in gallbladder inflammatory disorders and pathogenesis of gallstones. Urease-positive *Helicobacter* species are capable of precipitating calcium and may also promote the risk of gall stone formation by acting as a foreign body nidus.³⁵ *H. pylori* in gallbladder induces beta-glucuronidase, bacterial hydrolase, and phospholipase to deconjugate bile and hydrolyze

phosphatidylcholine, thus promoting the synthesis of free bilirubin, free bile acids, and free fatty acids. Urease positive helicobacter species precipitates free ionized calcium ion with free bilirubin to form calcium bilirubinate stones. Calcium bilirubinate, free bileacids, and free fatty acids are the major components of brown pigment stones.³⁶

Since *H. pylori* infection promotes the formation of gallstones, Zhang et al,³⁷ and Takahashi et al,³⁸ consider whether *H. pylori* eradication therapy can prevent the formation of gallstones, they both found a statistically significant trend in the reduction of gallstones among the patients who received helicobacter pylori eradication.

Conclusion:

Helicobacter pylori infection is found in patients treated for symptomatic gall stones. *Helicobacter pylori* infection is closely related to an increased risk of chronic cholecystitis and cholelithiasis. Treatment of helicobacter pylori infection is necessary to save the patients from post cholecystectomy symptoms.

Limitations: Due to the intrinsic limitations of a single-centered study, more accurate population-specific conclusions could have been drawn with larger-scaled research.

Conflict of interest: None

Funding source: None

Role and contribution of authors:

Nimra Ali, collected the data, references and did the initial write up.

Azfaruddin Qureshi, went through the article, made useful changes in introduction, discussion and result.

Sayed Ashraf Hassan, critically went through the article and made final changes.

Ramsha Fareed, collected the data and helped in introduction writing.

Farhina Salahuddin, collected the references and helped in discussion writing.

Narmeen Farooq Panjwani, collected the data, references and also helped in interpretation of data.

References:

1. Channa NA, Khand FD, Bhangwer MI, Leghari MH. Surgical incidence of cholelithiasis in hyderabad and adjoining areas (pakistan). *Pak J Med Sci.* 2004;20(1):13–17
2. Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. *GastroenterolClin North Am.* 2010;39:157–169, vii.
3. Chen CH, Huang MH, Yang JC, Nien CK, Etheredge GD, Yang CC, Yeh YH, Wu HS, Chou DA, Yueh SK. Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey. *J GastroenterolHepatol.* 2006;21:1737–1743.
4. Takahashi Y, Yamamichi N, Shimamoto T, Mochizuki S, Fujishiro M, Takeuchi C, Sakaguchi Y, Niimi K, Ono S, Kodashima S, et al. *Helicobacter pylori* infection is positively associated with gallstones: a large-scale cross-sectional study in Japan. *J Gastroenterol.* 2014;49:882–89
5. Devrajani BR, Muhammad AT, Shah SZA, Devrajani T, Das T. Frequency of gallstones in patients with diabetes mellitus: a hospital based multidisciplinary study. *Med Channel.* 2010;16(2):230–32.
6. Doraiswamy S, Kumar D, Sreeramulu PN, Suresh. Diagnosis of *Helicobacter pylori* in cholelithiasis and cholecystitis: by histology and serological association. *IntSurgJ* 2019;6:3986-90.
7. Gunasekaran P, Vinson I. *Helicobacter pylori* colonization of gallbladder in patients with symptomatic cholelithiasis. *IntSurgJ* 2017;4:2194-6.
8. Devarbhavi H, Nanivadekar S, Sawant P, Saraswathy K. Sensitivity of *Helicobacter pylori* isolates from Indian patients to differentantibacterial agents. *Indian J Gastroenterol.* 1998;17(1):S3.
9. E. A. Shaffer, "Epidemiology and risk factors for gallstonedisease: has the paradigm changed in the 21st century?"*Current Gastroenterology Reports*, vol. 7, no. 2, pp. 132–140,2005.
10. U. R. M. Bohr, D. Kuester, F. Meyer et al., "Low prevalence of *Helicobacteraceae* in gall-stone disease and gall-bladdercarcinoma in the German population," *Clinical Microbiologyand Infection*, vol. 13, no. 5, pp. 525–531, 2007.
11. M. Bulajic, P. Maisonneuve, W. Schneider-Brachert et al., "*Helicobacter pylori* and the risk of benign and malignantbiliary tract disease," *Cancer*, vol. 95, no. 9, pp. 1946–1953,2002.
12. RUPERT W LEONG *Helicobacter* species and hepatobiliary diseases May 2002*Alimentary Pharmacology & Therapeutics* 16(6):1037 – 1045.
13. Abro AH, Haider IZ, Ahmad S. *Helicobacter pylori* infection in patients with calcularcholecystitis: a hospital-based study. *J Ayub Med Coll Abbottabad* 2011;23(1):30-33
14. Batoolali khorsheed1, Sawsan M. Jabbar AL-Hasnawi2, Ali NayyefAssi. Prevalence of *Helicobacter pylori* among patients with cholelithiasis *International Journal of Medical Science and Current Research (IJMSCR)* Available online at: www.ijmscr.com Volume 2, Issue 5, Page No: 93-97 September-October 2019.
15. Li Cen, Jiaqi Pan, Boyan Zhou, Chaohui Yu, Youming Li, Weixing Chen, ZheShen *Helicobacter Pylori* infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis *Helicobacter* Volume23, Issue1 February 2018 e12457.
16. Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone forma-

- tion. *Gastroenterol* 2009; 136: 425–440.
17. Kawaguchi M, Saito T, Ohno H, Midorikawa S, Sanji T, Handa Y, Morita S, Yoshida H, Tsurui M, Misaka R, Hirota T, Saito M, Minami K. *J Gastroenterol*. 1996 Apr; 31(2):294-8.
 18. Srinivasan Doraiswamy, Dharmendra Kumar, P. N. Sreeramulu, Suresh. Diagnosis of *Helicobacter pylori* in cholelithiasis and cholecystitis: by histology and serological association. *International Surgery Journal Doraiswamy S et al. IntSurg J*. 2019 Nov;6(11):3986-3990
 19. Zhou D, Guan WB, Wang JD, Zhang Y, Gong W, Quan ZW. A comparative study of clinicopathological features between chronic cholecystitis patients with and without *Helicobacter pylori* infection in gallbladder mucosa. *PLoS One*. 2013; 8(7):e70265
 20. Cen L, Pan J, Zhou B, Yu C, Li Y, Chen W, Shen Z. Review of *Helicobacter Pylori* infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis. *Helicobacter*. 2018 Feb; 23(1):
 21. Yakoob, J., Khan, M., Abbas, Z., Jafri, W., Azmi, R., Ahmad, Z., Naeem, S., Lubbad, L. (2011). *Helicobacter pylori*: association with gall bladder disorders in Pakistan. *British Journal of Biomedical Science*, 68(2), 59-64.
 22. Bahri Abayli I, Salih Colakoglu, Mehmet Serin, Seyda Erdogan, Y Fatih Isiksal, Ilhan Tuncer, Fatih Koksak, Haluk Demiryurek. *Helicobacter pylori* in the etiology of cholesterol gallstones. *Clin Gastroenterol* 2005 Feb;39(2):134-7.
 23. R. W. Leong and J. J. Sung, "Review article: Helicobacter species and hepatobiliary diseases," *Alimentary Pharmacology & Therapeutics*, vol. 16, no. 6, pp. 1037–1045, 2002.
 24. P. H. Karagin, U. Stenram, T. Wadström, and A. Ljungh, "Helicobacter species and common gut bacterial DNA in gallbladder with cholecystitis," *World Journal of Gastroenterology*, vol. 16, no. 38, pp. 4817–4822, 2010.
 25. M. Y. Dar, S. Ali, A. H. Raina et al., "Association of *Helicobacter pylori* with hepatobiliary stone disease, a prospective case control study," *Indian Journal of Gastroenterology*, vol. 35, no. 5, pp. 343–346, 2016. SAT
 26. Siddique O, Ovalle A, Siddique AS, Moss SF. *Helicobacter pylori* infection: an update for the internist in the age of increasing global antibiotic resistance. *Am J Med*. 2018;131(5):473-479. doi:10.1016/j.amjmed.2017.12.024.
 27. Gisbert JP, de la Morena F, Abaira V. Accuracy of monoclonal stool antigen test for the diagnosis of *H. pylori* infection: a systematic review and meta-analysis. *Am J Gastroenterol*. 2006;101:1921–1930.
 28. Okuda M, Osaki T, Lin Y, Yonezawa H, Maekawa K, Kamiya S, Fukuda Y, Kikuchi S. Low prevalence and incidence of *Helicobacter pylori* infection in children: a population-based study in Japan. *Helicobacter*. 2015;20:133–138.
 29. Kesli R, Gokturk HS, Erbayrak M, Karabagli P, Terzi Y. Comparison of the diagnostic values of the 3 different stool antigen tests for the noninvasive diagnosis of *Helicobacter pylori* infection. *J Investig Med*. 2010;58:982–986.
 30. Shimoyama T. Stool antigen tests for the management of *Helicobacter pylori* infection. *World J Gastroenterol*. 2013;19:8188–8191.
 31. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of *Helicobacter pylori* infection—the Maastricht IV/ Florence Consensus Report. *Gut* 2012;61:646–64.
 32. Y.-K. Wang, F.-C. Kuo, C.-J. Liu et al., "Diagnosis of *Helicobacter pylori* infection: current options and developments," *World Journal of Gastroenterology*, vol. 21, no. 40, pp. 11221–11235, 2015.
 33. P. Sipos, H. Krisztina, A. Blázovics, and J. Fehér, "Cholecystitis, gallstones and free radical reactions in human gallbladder," *Medical Science Monitor*, vol. 7, no. 1, pp. 84–88, 2001.
 34. A. Kasprzak, A. Szmyt, A. Malkowski et al., "Analysis of immunohistochemical expression of proinflammatory cytokines (IL-1 α , IL-6, and TNF- α) in gallbladder mucosa: comparative study in acute and chronic calculous cholecystitis," *Folia Morphologica (Warsz)*, vol. 74, no. 1, pp. 65–72, 2015.
 35. Belzer, J. G. Kusters, E. J. Kuipers, and A. H. M. Van Vliet, "Urease induced calcium precipitation by *Helicobacter* species may initiate gallstone formation," *Gut*, vol. 55, no. 11, pp. 1678–1679, 2006.
 36. Y. Wang, M. Qi, C. Qin, and J. Hong, "of the biliary microbiome in gallstone disease," *Expert Review of Gastroenterology & Hepatology*, vol. 12, no. 12, pp. 1193–1205, 2018.
 37. F.-M. Zhang, C.-H. Yu, H.-T. Chen et al., "Helicobacter pylori infection is associated with gallstones: epidemiological survey in China," *World Journal of Gastroenterology*, vol. 21, no. 29, pp. 8912–8919, 2015.
 38. Y. Takahashi, N. Yamamichi, T. Shimamoto et al., "Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan," *Journal of Gastroenterology*, vol. 49, no. 5, pp. 882–889, 2014.